No coin nor oath required. For personal study only.
Adaptive immune response, impact of innate immunity, 4-g cognate interactions in adaptive immunity, ?-8 induction of costimulatory molecules, 6-7 innate immune system control of effector cytokines, 8 Adoptive T cell therapy, prospects, ?02-?08 generation of antigen-specific melanoma-reactive T cells, ?03-?04 genetic modification of antigen-specific T cells, 706 issues to consider when selecting target antigen(s), ?02-?03 precursor frequency of antigen-specific tumor-reactive T cells, 702-703 prevalence and heterogeneity of antigen expression by tumor cells, 703 tumor antigens expressed on normal tissues and potential for autoimmune toxicity, ?03 lessons learned from adoptive T cell therapy of human viral diseases, ?04-705 cytomegalovirus infection, ?04 Epstein-Barr virus associated lymphomas, 705 tumor antigens as targets for adoptive therapy, 702 Allergen gene transfer, 800-804 DNA-based immunization and modulation of allergic response, 801-802 modulation of airway allergic responses, 801-802 modulation of antigen-specific IgE synthesis, 801 implication for potential prophylaxis and treatment of allergic diseases, 802 Allergens, environmental, different classes, development of long term tolerance versus sensitisation during perinatal period, 782-787 basic principles defined in animal models, ?83 development of T-cell memory against dietary and inhalant allergens in humans: where, when and how? ?83-?84 immune deviation of Th2 responses during infancy: risk factors for failure, 784-785 responder phenotype a la the Thl/Th2 paradigm, ?82-783 AIIograft rejection, acceptance, and tolerance, CD40 pathway, 641-64? AIIotransplantation and gene therapy, 662-668 Alternative antigen processing pathways in anti-infective immunity, 462-469 Anti-CD3 mAbs, T cell inactivation and cytokine deviation produced by, 648-654 development of FcR-nonbinding anti-CD3 mAbs, 648-649 mechanism of action, 649-651 partial TCR signals, 649-650 T cell unresponsiveness and cytokine deviation, 650-651 model, 651-652 Anti-lgE antibodies, therapeutic potential, 805-814 clinical results with humanized anti-human IgE antibodies, 810-811 clinical effect on asthmatic response after provocation with allergen, 811 clinical effect on rhinitis symptoms, 811 effect on serum IgE levels, 810 reduction of Fcepsilon RI expression after anti-lgE treatment, 811 concept of non-anaphylactogenic anti-lgE antibodies as therapeutic agents, 805-806 effect of anti-lgE antibodies on IgE expressing memory B cells in vivo, 808 effect on defense against parasitic infections, 809 effect of non-anaphylactogenic anti-lgE antibody on immune response in mice, 808
๐ SIMILAR VOLUMES
Aspartic proteases engineered, structure and function relationships, 422-427 evolutionary relationships of retrovirus with eukaryote aspartic proteases, 422 retroviral aspartyl protease, 403-406 site-directed mutagenesis, 424-426 Aspergillus oryzae, 207 ATPases of metal transport, in genetic testing
Adaptor proteins in lymphocyte antigen-receptor signaling, 337-344 Cbl and Crk, 339-340 Grb and She, 337-338 LAT (pp36), 339 SLP-76, SLAP-l 30 (Fyb), and SKAP55, 338-339 Adjuvant-induced arthritis models, genetic susceptibility, 713-714 Allergic respiratory disease, indoor versus outdoor allergens,